The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Durect Corp (DRRX) navigates a challenging financial landscape with strategic initiatives and promising clinical developments ...

U.S. President Donald Trump's administration has asked oil and biofuels producers to hash out a deal on the next phase of the ...

"Phase One" of the development is expected to begin later this summer with four of the slides and a new shaded area that will ...

Mihir Vora, CIO at Trust Mutual Fund, discusses market trends, highlighting the end of the correction phase and the potential ...

The majority of the 374km metro network being developed in the Mumbai Metropolitan Region (MMR) is expected to be operational ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.12. Operator: Good afternoon, everyone.

For instance, Josh Giddey has shown remarkable versatility; he recorded 10 points, 8 rebounds, and 6 assists against the Lakers, demonstrating significant contributions on both ends of the floor.

Despite rising SG&A and interest expenses, Accel's revenue grew 5% to $1.231 billion in FY 2024, with strong sales per ...

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) ...

Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 T ...